Today: 17 July 2026
Browse Category

Stock Market 10 February 2026

China’s Arexvy review puts GSK stock back in focus before London trade

China’s Arexvy review puts GSK stock back in focus before London trade

GSK plc shares are set to trade with new vaccine developments on the radar. The company reported that China’s Center for Drug Evaluation has taken up its application for Arexvy, the RSV shot designed for people 60 and up. GSK noted that, should approval come through, Arexvy would mark the first vaccine in China targeting RSV-linked lower respiratory tract disease in that demographic.
Go toTop